Loading company…
Riskpilot
← Back to search
Sign in
Get full access
PharmaCCX AB
AB
In liquidation
Org 5592107493
Other information service activities n.e.c. · NACE 6399
Est. 2019
1 employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2022
SEK 2,3M
-20% vs 2021
EBITDA margin
0.4%
+43% vs 2021
Equity ratio
17.3%
Financial strength
Net profit 2022
SEK 0
1 employees
EBITDA — year on year
SEK millions
0M
0M
1M
1M
1M
0M
2020
0M
0%
2021
0M
0%
2022
Key figures
Annual report 2022
Revenue
SEK 2,3M
-20%
EBITDA
SEK 10K
+43%
Net profit
SEK 0
—
Total assets
SEK 173K
-94%
Equity
SEK 30K
+0%
Employees
1
—
Company information
Legal name
PharmaCCX AB
Org number
5592107493
Legal form
Aktiebolag
NACE code
6399 · Other information service activities n.e.c.
Founded
1 juli 2019
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget ska driva en digital mjukvarubaserad plattform för att underlätta prisförhandlingar för läkemedel samt därmed förenlig verksamhet.
Contact
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Other information service activities n.e.c.
Companies in
All Sweden companies
Revenue
SEK millions
0M
1M
2M
3M
5M
4M
2020
3M
2021
2M
2022
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2020
0M
2021
0M
2022
Income statement
SEK thousands
Item
2020
2021
2022
Revenue
3 575
2 813
2 250
Staff expenses
—
—
—
EBITDA
−17
7
10
Depreciation & amort.
−0
−0
−0
EBIT
−17
7
10
Net financials
−3
−7
−10
Profit before tax
−20
0
0
Tax
−0
−0
−0
Net profit
−20
0
0
Balance sheet
SEK thousands
Item
2020
2021
2022
Total assets
222
2 888
173
Equity
30
30
30
Long-term debt
0
2 597
0
Short-term debt
192
261
143
Total debt
192
2 858
143
Financial ratios
5-year trend
EBITDA margin
0.4%
This company
15.8%
Market median
-97% vs market
2020
2022
Equity ratio
17.3%
This company
38.2%
Market median
-55% vs market
2020
2022
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
2020
2022
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
2020
2022
Asset turnover
13.01×
This company
1.12×
Market median
+1062% vs market
2020
2022
Debt / equity
4.77×
This company
0.62×
Market median
-669% vs market
2020
2022
Annual reports & filings
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Age
Other directorships
LJ
Lars Johan Linder
Liquidator
Liquidator
2023
—
—
RA
Richard Arne Bergström
External Signatory
External Signatory
2022
—
—
Board of directors
Non-executive oversight
Name
Role
Member since
Age
Other directorships
CF
Carl Fredrik Moen
Board of Directors
2022
—
—
HB
Helena Bowden
Deputy Board Member
2022
—
—
NJ
Nathan John Sigworth
Chairman
2022
—
—
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of PharmaCCX AB also hold positions in
0
other companies.
Person
Role here
Other companies
Lars Johan Linder
Liquidator
0 companies
Richard Arne Bergström
External Signatory
0 companies
Carl Fredrik Moen
Board of Directors
0 companies
Helena Bowden
Deputy Board Member
0 companies
Nathan John Sigworth
Chairman
0 companies